Avanos Medical, Inc. (AVNS) Stock Price & Analysis
Avanos Medical, Inc. (AVNS) rose 0.12% to USD 25.03 as of June 10, 2026 at 04:23 UTC, according to Nexqual real-time market data.
AVNS last closed at USD 25; the session ranged USD 25–25.06 on volume of 633,938 shares. Market capitalization is $1.17B, with a 52-week range of USD 9.3–25.49 (NYQ). Source: Nexqual, June 10, 2026 at 04:23 UTC.
Key Statistics (as of June 10, 2026 at 04:23 UTC)
| Price | USD 25.03 |
|---|---|
| Change | ▲ 0.12% (up) |
| Previous Close | USD 25 |
| Open | USD 25.06 |
| Day Range | USD 25 – 25.06 |
| 52-Week Range | USD 9.3 – 25.49 |
| Volume | 633,938 shares |
| Market Cap | $1.17B |
| Exchange | NYQ |
Technical Analysis (AVNS)
Nexqual's technical model rates AVNS "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 04:23 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 64.63 (neutral) |
| vs SMA50 | Above (USD 22.37) |
| MACD | 0.61 (positive) |
Analyst Ratings (AVNS)
Wall Street analysts rate AVNS "None", per Nexqual as of June 10, 2026 at 04:23 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (AVNS)
| Next Earnings Date | 2026-05-05 |
|---|---|
| EPS Estimate | USD 0.16 |
| Revenue Estimate | $173.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.22 vs est 0.14 ▲ beat |
| 2025-12-31 | USD 0.29 vs est 0.25 ▲ beat |
| 2025-09-30 | USD 0.22 vs est 0.12 ▲ beat |
| 2025-06-30 | USD 0.17 vs est 0.15 ▲ beat |
Source: Nexqual, June 10, 2026 at 04:23 UTC.
Financials & Fundamentals (AVNS)
| Total Revenue | $715.90M |
|---|---|
| Revenue Growth (YoY) | +8.80% |
| Gross Margin | +50.05% |
| Operating Margin | +5.38% |
| Profit Margin | -10.39% |
| ROE | -9.18% |
| Debt / Equity | 17.7 |
| Current Ratio | 2.48 |
| Total Cash | $65.60M |
| Total Debt | $138.40M |
| Free Cash Flow | $17.05M |
Source: Nexqual, June 10, 2026 at 04:23 UTC.
Financial Health Score (AVNS)
Nexqual rates Avanos Medical, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:23 UTC.
| Growth | Mixed — Revenue +1.9% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 50%, operating 5% |
| Balance Sheet | Strong — $66M cash vs $138M debt |
| Cash Flow | Mixed — FCF $17M, slim 2.4% margin |
| Efficiency | Critical — ROE -9%, ROA 0.9% |
Ownership (AVNS)
| Insider Ownership | +4.75% |
|---|---|
| Institutional Ownership | +90.86% |
| Shares Outstanding | 46.82M |
| Float | 45.93M |
| Short % of Float | +3.32% |
Source: Nexqual, June 10, 2026 at 04:23 UTC.
Leadership (AVNS)
Avanos Medical, Inc. is led by David C. Pacitti (age 59), CEO & Director, per Nexqual as of June 10, 2026 at 04:23 UTC.
| CEO & Director | David C. Pacitti (age 59) |
|---|---|
| Senior VP & CFO | Scott Michael Galovan (age 46) |
| Senior Vice President of Operations | Sigfrido Delgado (age 48) |
| Vice President of Corporate Finance & Treasurer | Jason M. Pickett (age 53) |
| Vice President of Corporate Communications & Community Relations | Katrine Kubis |
Major Backers & Investors (AVNS)
Notable institutional backers of Avanos Medical, Inc. include T. Rowe Price, Brown Advisory Inc., Armistice Capital, LLC, according to Nexqual as of June 10, 2026 at 04:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 17.44% |
| Brown Advisory Inc. | 7.31% |
| Armistice Capital, LLC | 4.27% |
| -Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 3.95% |
| Acadian Asset Management. LLC | 2.59% |
| Thrivent Financial For Lutherans | 2.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 22.94% |
| Vanguard Group | 10.97% |
| Dimensional Fund Advisors | 4.38% |
| State Street | 4.21% |
Source: Nexqual, June 10, 2026 at 04:23 UTC.
From Avanos Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.
- It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
- The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems.
- In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; and Trident and Esentec RFA radiofrequency ablation products to treat chronic pain conditions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VREX | Varex Imaging Corporation | USD 10.62 | ▲ 5.25% |
| ITGR | Integer Holdings Corporation | USD 94.1 | ▲ 2.3% |
| LIVN | LivaNova PLC | USD 77.17 | ▲ 6.65% |
| CNMD | CONMED Corporation | USD 36.9 | ▲ 4.95% |
| KIDS | OrthoPediatrics Corp. | USD 18.49 | ▲ 0.93% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:23 UTC. This page is informational and not investment advice.